{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:52:34Z","timestamp":1790401954978,"version":"4.1.0"},"reference-count":116,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1097\/spc.0000000000000204","type":"journal-article","created":{"date-parts":[[2016,4,19]],"date-time":"2016-04-19T17:14:06Z","timestamp":1461086046000},"page":"119-128","source":"Crossref","is-referenced-by-count":47,"title":["Chemotherapy-induced painful neuropathy"],"prefix":"10.1097","volume":"10","author":[{"given":"Holly L.","family":"Hopkins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie A.","family":"Duggett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah J.L.","family":"Flatters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20211004","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.pain.2004.01.021","article-title":"Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients","volume":"109","author":"Dougherty","year":"2004","journal-title":"Pain"},{"key":"R2-3-20211004","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/jnci\/djh323","article-title":"Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma","volume":"96","author":"Vasey","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"R3-3-20211004","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.critrevonc.2008.01.008","article-title":"Peripheral nerve damage associated with administration of taxanes in patients with cancer","volume":"66","author":"Argyriou","year":"2008","journal-title":"Crit Rev Oncol Hematol"},{"key":"R4-3-20211004","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1080\/02841860701355055","article-title":"Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer","volume":"46","author":"Argyriou","year":"2007","journal-title":"Acta Oncol"},{"key":"R5-3-20211004","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.pain.2009.03.024","article-title":"Thermal hyperalgesia as a marker of oxaliplatin neurotoxicity: a prospective quantified sensory assessment study","volume":"144","author":"Attal","year":"2009","journal-title":"Pain"},{"key":"R6-3-20211004","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.jpain.2009.04.006","article-title":"Chemotherapy-induced peripheral neuropathy as a predictor of neuropathic pain in breast cancer patients previously treated with paclitaxel","volume":"10","author":"Reyes-Gibby","year":"2009","journal-title":"J Pain"},{"key":"R7-3-20211004","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/(SICI)1097-4598(199706)20:6<750::AID-MUS15>3.0.CO;2-Y","article-title":"Progression of paclitaxel-induced neuropathy following discontinuation of treatment","volume":"20","author":"van den Bent","year":"1997","journal-title":"Muscle Nerve"},{"key":"R8-3-20211004","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.jpain.2011.04.008","article-title":"Follow-up psychophysical studies in bortezomib-related chemoneuropathy patients","volume":"12","author":"Boyette-Davis","year":"2011","journal-title":"J Pain"},{"key":"R9-3-20211004","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1200\/JCO.2013.54.0914","article-title":"Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline","volume":"32","author":"Hershman","year":"2014","journal-title":"J Clin Oncol"},{"key":"R10-3-20211004","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.critrevonc.2011.04.012","article-title":"Chemotherapy-induced peripheral neurotoxicity (CIPN): an update","volume":"82","author":"Argyriou","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"key":"R11-3-20211004","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.pain.2014.09.020","article-title":"Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis","volume":"155","author":"Seretny","year":"2014","journal-title":"Pain"},{"key":"R12-3-20211004","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/375424a0","article-title":"Structure of tubulin at 6.5 A and location of the taxol-binding site","volume":"375","author":"Nogales","year":"1995","journal-title":"Nature"},{"key":"R13-3-20211004","doi-asserted-by":"crossref","first-page":"730","DOI":"10.2174\/156800907783220417","article-title":"How do microtubule-targeted drugs work? An overview","volume":"7","author":"Jordan","year":"2007","journal-title":"Curr Cancer Drug Targets"},{"key":"R14-3-20211004","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/oxfordjournals.annonc.a058903","article-title":"Paclitaxel (TaxolTM) and docetaxel (TaxotereTM): not simply two of a kind","volume":"5","author":"Verweij","year":"1994","journal-title":"Ann Oncol"},{"key":"R15-3-20211004","doi-asserted-by":"crossref","first-page":"5542","DOI":"10.1200\/JCO.2005.02.027","article-title":"Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer","volume":"23","author":"Jones","year":"2005","journal-title":"J Clin Oncol"},{"key":"R16-3-20211004","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/BF01148489","article-title":"Taxol-induced neuropathy: short-term effects of local injection","volume":"13","author":"Roytta","year":"1984","journal-title":"J Neurocytol"},{"key":"R17-3-20211004","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/BF01150269","article-title":"Taxol-induced neuropathy: further ultrastructural studies of nerve fibre changes in situ","volume":"14","author":"Roytta","year":"1985","journal-title":"J Neurocytol"},{"key":"R18-3-20211004","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/BF01611731","article-title":"Taxol-induced neuropathy: chronic effects of local injection","volume":"15","author":"Roytta","year":"1986","journal-title":"J Neurocytol"},{"key":"R19-3-20211004","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0304-3959(01)00363-3","article-title":"A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel","volume":"94","author":"Polomano","year":"2001","journal-title":"Pain"},{"key":"R20-3-20211004","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.pain.2004.01.029","article-title":"Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy","volume":"109","author":"Flatters","year":"2004","journal-title":"Pain"},{"key":"R21-3-20211004","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0306-4522(01)00425-0","article-title":"Role of protein kinase Cepsilon and protein kinase A in a model of paclitaxel-induced painful peripheral neuropathy in the rat","volume":"108","author":"Dina","year":"2001","journal-title":"Neuroscience"},{"key":"R22-3-20211004","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0006-8993(00)02910-3","article-title":"Description of a short-term Taxol-induced nociceptive neuropathy in rats","volume":"887","author":"Authier","year":"2000","journal-title":"Brain Res"},{"key":"R23-3-20211004","first-page":"137","article-title":"Effect on the peripheral nervous system of the short-term intravenous administration of paclitaxel in the rat","volume":"18","author":"Cavaletti","year":"1997","journal-title":"Neurotoxicology"},{"key":"R24-3-20211004","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/ana.410290115","article-title":"Nerve growth factor prevents toxic neuropathy in mice","volume":"29","author":"Apfel","year":"1991","journal-title":"Ann Neurol"},{"key":"R25-3-20211004","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1248\/bpb.32.732","article-title":"Mechanical allodynia induced by paclitaxel, oxaliplatin and vincristine: different effectiveness of gabapentin and different expression of voltage-dependent calcium channel alpha(2)delta-1 subunit","volume":"32","author":"Gauchan","year":"2009","journal-title":"Biol Pharm Bull"},{"key":"R26-3-20211004","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1254\/jphs.08325SC","article-title":"Effects of the prostaglandin E1 analog limaprost on mechanical allodynia caused by chemotherapeutic agents in mice","volume":"109","author":"Gauchan","year":"2009","journal-title":"J Pharmacol Sci"},{"key":"R27-3-20211004","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1016\/j.lfs.2004.01.002","article-title":"Paclitaxel-induced neuropathic hypersensitivity in mice: responses in 10 inbred mouse strains","volume":"74","author":"Smith","year":"2004","journal-title":"Life Sci"},{"key":"R28-3-20211004","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s11596-012-1001-y","article-title":"Pregabalin attenuates docetaxel-induced neuropathy in rats","volume":"32","author":"Peng","year":"2012","journal-title":"J Huazhong Univ Sci Technolog Med Sci"},{"key":"R29-3-20211004","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1529-8027.2009.00204.x","article-title":"Docetaxel-induced peripheral neuropathy: protective effects of dihydroprogesterone and progesterone in an experimental model","volume":"14","author":"Roglio","year":"2009","journal-title":"J Peripher Nerv Syst"},{"key":"R30-3-20211004","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/ana.410430111","article-title":"Physiological characterization of Taxol-induced large-fiber sensory neuropathy in the rat","volume":"43","author":"Cliffer","year":"1998","journal-title":"Ann Neurol"},{"key":"R31-3-20211004","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/1097-0142(19950301)75:5<1141::AID-CNCR2820750514>3.0.CO;2-U","article-title":"Peripheral neurotoxicity of taxol in patients previously treated with cisplatin","volume":"75","author":"Cavaletti","year":"1995","journal-title":"Cancer"},{"key":"R32-3-20211004","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.pain.2006.01.037","article-title":"Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: evidence for mitochondrial dysfunction","volume":"122","author":"Flatters","year":"2006","journal-title":"Pain"},{"key":"R33-3-20211004","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.expneurol.2006.07.022","article-title":"Intravenous paclitaxel administration in the rat induces a peripheral sensory neuropathy characterized by macrophage infiltration and injury to sensory neurons and their supporting cells","volume":"203","author":"Peters","year":"2007","journal-title":"Exp Neurol"},{"key":"R34-3-20211004","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/oxfordjournals.annonc.a059220","article-title":"Paclitaxel-induced neuropathy","volume":"6","author":"Postma","year":"1995","journal-title":"Ann Oncol"},{"key":"R35-3-20211004","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1097\/00001756-199904060-00013","article-title":"Pain related behaviour during vincristine-induced neuropathy in rats","volume":"10","author":"Authier","year":"1999","journal-title":"Neuroreport"},{"key":"R36-3-20211004","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/ana.10300","article-title":"WldS mice are resistant to paclitaxel (taxol) neuropathy","volume":"52","author":"Wang","year":"2002","journal-title":"Ann Neurol"},{"key":"R38-3-20211004","first-page":"4","article-title":"Oxaliplatin: mechanism of action and antineoplastic activity","volume":"25","author":"Raymond","year":"1998","journal-title":"Semin Oncol"},{"key":"R39-3-20211004","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jpain.2008.12.003","article-title":"Comparison of oxaliplatin- and cisplatin-induced painful peripheral neuropathy in the rat","volume":"10","author":"Joseph","year":"2009","journal-title":"J Pain"},{"key":"R40-3-20211004","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/j.pain.2011.02.051","article-title":"Oxaliplatin elicits mechanical and cold allodynia in rodents via TRPA1 receptor stimulation","volume":"152","author":"Nassini","year":"2011","journal-title":"Pain"},{"key":"R41-3-20211004","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.neulet.2009.04.029","article-title":"Involvement of increased expression of transient receptor potential melastatin 8 in oxaliplatin-induced cold allodynia in mice","volume":"458","author":"Gauchan","year":"2009","journal-title":"Neurosci Lett"},{"key":"R42-3-20211004","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1248\/bpb.b14-00581","article-title":"Milnacipran inhibits oxaliplatin-induced mechanical allodynia through spinal action in mice","volume":"38","author":"Andoh","year":"2015","journal-title":"Biol Pharm Bull"},{"key":"R43-3-20211004","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1744-8069-8-55","article-title":"Acute cold hypersensitivity characteristically induced by oxaliplatin is caused by the enhanced responsiveness of TRPA1 in mice","volume":"8","author":"Zhao","year":"2012","journal-title":"Mol Pain"},{"key":"R44-3-20211004","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1254\/jphs.13249SC","article-title":"Pharmacological characterization of standard analgesics on oxaliplatin-induced acute cold hypersensitivity in mice","volume":"124","author":"Zhao","year":"2014","journal-title":"J Pharmacol Sci"},{"key":"R45-3-20211004","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/emmm.201100134","article-title":"Oxaliplatin-induced cold hypersensitivity is due to remodelling of ion channel expression in nociceptors","volume":"3","author":"Descoeur","year":"2011","journal-title":"EMBO Mol Med"},{"key":"R47-3-20211004","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1254\/jphs.14058FP","article-title":"Gabapentin prevents oxaliplatin-induced mechanical hyperalgesia in mice","volume":"125","author":"Ohsawa","year":"2014","journal-title":"J Pharmacol Sci"},{"key":"R48-3-20211004","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.pbb.2014.03.025","article-title":"Antiallodynic and antihyperalgesic activity of 3-[4-(3-trifluoromethyl\u2013phenyl)piperazin-1-yl]-dihydrofuran-2-one compared to pregabalin in chemotherapy-induced neuropathic pain in mice","volume":"122","author":"Salat","year":"2014","journal-title":"Pharmacol Biochem Behav"},{"key":"R49-3-20211004","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.tox.2007.02.013","article-title":"Behavioral and immunohistological assessment of painful neuropathy induced by a single oxaliplatin injection in the rat","volume":"234","author":"Ling","year":"2007","journal-title":"Toxicology"},{"key":"R50-3-20211004","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/FBP.0000000000000026","article-title":"Assessment of thermal sensitivity in rats using the thermal place preference test: description and application in the study of oxaliplatin-induced acute thermal hypersensitivity and inflammatory pain models","volume":"25","author":"Balayssac","year":"2014","journal-title":"Behav Pharmacol"},{"key":"R51-3-20211004","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1248\/bpb.b12-00887","article-title":"Salmon calcitonin reduces oxaliplatin-induced cold and mechanical allodynia in rats","volume":"36","author":"Aoki","year":"2013","journal-title":"Biol Pharm Bull"},{"key":"R52-3-20211004","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.neuropharm.2008.06.007","article-title":"Comparative antiallodynic activity of morphine, pregabalin and lidocaine in a rat model of neuropathic pain produced by one oxaliplatin injection","volume":"55","author":"Ling","year":"2008","journal-title":"Neuropharmacology"},{"key":"R53-3-20211004","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.expneurol.2011.02.019","article-title":"Protection against oxaliplatin-induced mechanical hyperalgesia and intraepidermal nerve fiber loss by minocycline","volume":"229","author":"Boyette-Davis","year":"2011","journal-title":"Exp Neurol"},{"key":"R54-3-20211004","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/1744-8069-9-53","article-title":"The antioxidant effects of the flavonoids rutin and quercetin inhibit oxaliplatin-induced chronic painful peripheral neuropathy","volume":"9","author":"Azevedo","year":"2013","journal-title":"Mol Pain"},{"key":"R55-3-20211004","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.neuroscience.2011.12.023","article-title":"Characterization of oxaliplatin-induced chronic painful peripheral neuropathy in the rat and comparison with the neuropathy induced by paclitaxel","volume":"203","author":"Xiao","year":"2012","journal-title":"Neuroscience"},{"key":"R56-3-20211004","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.expneurol.2011.08.016","article-title":"Functional deficits in peripheral nerve mitochondria in rats with paclitaxel- and oxaliplatin-evoked painful peripheral neuropathy","volume":"232","author":"Zheng","year":"2011","journal-title":"Exp Neurol"},{"key":"R57-3-20211004","first-page":"493","article-title":"Gabapentin prevents oxaliplatin-induced central sensitization in the dorsal horn neurons in rats","volume":"18","author":"Ruyang","year":"2015","journal-title":"Iran J Basic Med Sci"},{"key":"R58-3-20211004","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.neulet.2014.08.005","article-title":"Morphine and oxycodone, but not fentanyl, exhibit antinociceptive effects mediated by G-protein inwardly rectifying potassium (GIRK) channels in an oxaliplatin-induced neuropathy rat model","volume":"580","author":"Kanbara","year":"2014","journal-title":"Neurosci Lett"},{"key":"R59-3-20211004","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1254\/jphs.14134FP","article-title":"Establishment of opioid-induced rewarding effects under oxaliplatin- and paclitaxel-induced neuropathy in rats","volume":"126","author":"Mori","year":"2014","journal-title":"J Pharmacol Sci"},{"key":"R60-3-20211004","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.bbr.2015.04.038","article-title":"The long-term impact of oxaliplatin chemotherapy on rodent cognition and peripheral neuropathy","volume":"291","author":"Fardell","year":"2015","journal-title":"Behav Brain Res"},{"key":"R61-3-20211004","first-page":"2681","article-title":"Acetyl-L-carnitine prevents and reverts experimental chronic neurotoxicity induced by oxaliplatin, without altering its antitumor properties","volume":"25","author":"Ghirardi","year":"2005","journal-title":"Anticancer Res"},{"key":"R62-3-20211004","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s13181-012-0239-x","article-title":"The effect of curcumin on oxaliplatin and cisplatin neurotoxicity in rats: some behavioral, biochemical, and histopathological studies","volume":"9","author":"Al Moundhri","year":"2013","journal-title":"J Med Toxicol"},{"key":"R63-3-20211004","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jpain.2008.01.335","article-title":"Oxaliplatin acts on IB4-positive nociceptors to induce an oxidative stress-dependent acute painful peripheral neuropathy","volume":"9","author":"Joseph","year":"2008","journal-title":"J Pain"},{"key":"R64-3-20211004","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1744-8069-7-29","article-title":"Multimodal assessment of painful peripheral neuropathy induced by chronic oxaliplatin-based chemotherapy in mice","volume":"7","author":"Renn","year":"2011","journal-title":"Mol Pain"},{"key":"R65-3-20211004","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1744-8069-5-9","article-title":"Mice with cisplatin and oxaliplatin-induced painful neuropathy develop distinct early responses to thermal stimuli","volume":"5","author":"Ta","year":"2009","journal-title":"Mol Pain"},{"key":"R66-3-20211004","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.pain.2006.09.016","article-title":"Behavioral and pharmacological description of oxaliplatin-induced painful neuropathy in rat","volume":"128","author":"Ling","year":"2007","journal-title":"Pain"},{"key":"R67-3-20211004","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1254\/jphs.14133FP","article-title":"The contribution of Gi\/o protein to opioid antinociception in an oxaliplatin-induced neuropathy rat model","volume":"126","author":"Kanbara","year":"2014","journal-title":"J Pharmacol Sci"},{"key":"R68-3-20211004","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1254\/jphs.12006SC","article-title":"Repeated administration of amitriptyline reduces oxaliplatin-induced mechanical allodynia in rats","volume":"118","author":"Sada","year":"2012","journal-title":"J Pharmacol Sci"},{"key":"R69-3-20211004","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1254\/jphs.10012SC","article-title":"Mexiletine reverses oxaliplatin-induced neuropathic pain in rats","volume":"112","author":"Egashira","year":"2010","journal-title":"J Pharmacol Sci"},{"key":"R70-3-20211004","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1007\/s11064-013-1103-3","article-title":"Repeated administration of mirtazapine attenuates oxaliplatin-induced mechanical allodynia and spinal NR2B up-regulation in rats","volume":"38","author":"Liu","year":"2013","journal-title":"Neurochem Res"},{"key":"R71-3-20211004","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/01.anes.0000435634.34709.65","article-title":"Characterization of acute and chronic neuropathies induced by oxaliplatin in mice and differential effects of a novel mitochondria-targeted antioxidant on the neuropathies","volume":"120","author":"Toyama","year":"2014","journal-title":"Anesthesiology"},{"key":"R72-3-20211004","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.brainres.2008.07.022","article-title":"Behavioral and electrophysiological studies in rats with cisplatin-induced chemoneuropathy","volume":"1230","author":"Cata","year":"2008","journal-title":"Brain Res"},{"key":"R73-3-20211004","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00280-001-0382-6","article-title":"The experimental neuroprotectant leukaemia inhibitory factor (LIF) does not compromise antitumour activity of paclitaxel, cisplatin and carboplatin","volume":"48","author":"Boyle","year":"2001","journal-title":"Cancer Chemother Pharmacol"},{"key":"R74-3-20211004","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.phrs.2012.10.013","article-title":"Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment","volume":"67","author":"Guindon","year":"2013","journal-title":"Pharmacol Res"},{"key":"R75-3-20211004","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.lfs.2007.06.012","article-title":"WIN 55\u200a212-2 prevents mechanical allodynia but not alterations in feeding behaviour induced by chronic cisplatin in the rat","volume":"81","author":"Vera","year":"2007","journal-title":"Life Sci"},{"key":"R76-3-20211004","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1213\/ANE.0b013e31826e1007","article-title":"Persistent hyperalgesia in the cisplatin-treated mouse as defined by threshold measures, the conditioned place preference paradigm, and changes in dorsal root ganglia activated transcription factor 3: the effects of gabapentin, ketorolac, and etanercept","volume":"116","author":"Park","year":"2013","journal-title":"Anesth Analg"},{"key":"R77-3-20211004","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1002\/ejp.679","article-title":"Differences in cisplatin-induced mechanical allodynia in male and female mice","volume":"19","author":"Woller","year":"2015","journal-title":"Eur J Pain"},{"key":"R78-3-20211004","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1023\/A:1006124917643","article-title":"Amelioration of experimental cisplatin and paclitaxel neuropathy with glutamate","volume":"41","author":"Boyle","year":"1999","journal-title":"J Neurooncol"},{"key":"R79-3-20211004","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1023\/A:1005756023082","article-title":"Experimental cisplatin neuronopathy in rats and the effect of retinoic acid administration","volume":"36","author":"Tredici","year":"1998","journal-title":"J Neurooncol"},{"key":"R80-3-20211004","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12990-015-0031-4","article-title":"Tolerance to the antinociceptive effects of chronic morphine requires c-Jun N-terminal kinase","volume":"11","author":"Marcus","year":"2015","journal-title":"Mol Pain"},{"key":"R81-3-20211004","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0014-4886(03)00003-7","article-title":"An animal model of nociceptive peripheral neuropathy following repeated cisplatin injections","volume":"182","author":"Authier","year":"2003","journal-title":"Exp Neurol"},{"key":"R82-3-20211004","first-page":"6316","article-title":"The proteasome as a target for cancer therapy","volume":"9","author":"Voorhees","year":"2003","journal-title":"Clin Cancer Res"},{"key":"R83-3-20211004","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0093-7754(01)90034-X","article-title":"Proteasome inhibition in cancer: development of PS-341","volume":"28","author":"Adams","year":"2001","journal-title":"Semin Oncol"},{"key":"R84-3-20211004","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.3109\/10428194.2010.487959","article-title":"Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches","volume":"51","author":"Engelhardt","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"R85-3-20211004","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0305-7372(03)00079-3","article-title":"Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib","volume":"29","author":"Cusack","year":"2003","journal-title":"Cancer Treat Rev"},{"key":"R86-3-20211004","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.2217\/fon.14.30","article-title":"Efficacy of therapy with bortezomib in solid tumors: a review based on 32 clinical trials","volume":"10","author":"Huang","year":"2014","journal-title":"Future Oncol"},{"key":"R87-3-20211004","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1254\/jphs.13274FP","article-title":"Gabapentin inhibits bortezomib-induced mechanical allodynia through supraspinal action in mice","volume":"124","author":"Kitamura","year":"2014","journal-title":"J Pharmacol Sci"},{"key":"R88-3-20211004","doi-asserted-by":"crossref","first-page":"6370","DOI":"10.1038\/srep06370","article-title":"Electrophysiological, behavioral and histological characterization of paclitaxel, cisplatin, vincristine and bortezomib-induced neuropathy in C57Bl\/6 mice","volume":"4","author":"Boehmerle","year":"2014","journal-title":"Sci Rep"},{"key":"R89-3-20211004","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jphs.2015.08.006","article-title":"Behavioral and pharmacological characteristics of bortezomib-induced peripheral neuropathy in rats","volume":"129","author":"Yamamoto","year":"2015","journal-title":"J Pharmacol Sci"},{"key":"R90-3-20211004","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.brainres.2014.06.013","article-title":"Altered discharges of spinal neurons parallel the behavioral phenotype shown by rats with bortezomib related chemotherapy induced peripheral neuropathy","volume":"1574","author":"Robinson","year":"2014","journal-title":"Brain Res"},{"key":"R91-3-20211004","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.expneurol.2012.08.023","article-title":"Mitotoxicity and bortezomib-induced chronic painful peripheral neuropathy","volume":"238","author":"Zheng","year":"2012","journal-title":"Exp Neurol"},{"key":"R92-3-20211004","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ejpain.2009.07.001","article-title":"Bortezomib-induced painful neuropathy in rats: a behavioral, neurophysiological and pathological study in rats","volume":"14","author":"Meregalli","year":"2010","journal-title":"Eur J Pain"},{"key":"R93-3-20211004","doi-asserted-by":"crossref","first-page":"180428","DOI":"10.1155\/2014\/180428","article-title":"Bortezomib treatment produces nocifensive behavior and changes in the expression of TRPV1, CGRP, and substance P in the rat DRG, spinal cord, and sciatic nerve","volume":"2014","author":"Quartu","year":"2014","journal-title":"Biomed Res Int"},{"key":"R94-3-20211004","doi-asserted-by":"crossref","first-page":"e72995","DOI":"10.1371\/journal.pone.0072995","article-title":"Bortezomib-induced painful peripheral neuropathy: an electrophysiological, behavioral, morphological and mechanistic study in the mouse","volume":"8","author":"Carozzi","year":"2013","journal-title":"PLoS One"},{"key":"R95-3-20211004","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.expneurol.2010.02.006","article-title":"Neurophysiological, histological and immunohistochemical characterization of bortezomib-induced neuropathy in mice","volume":"223","author":"Bruna","year":"2010","journal-title":"Exp Neurol"},{"key":"R96-3-20211004","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jpain.2006.09.014","article-title":"Quantitative sensory findings in patients with bortezomib-induced pain","volume":"8","author":"Cata","year":"2007","journal-title":"J Pain"},{"key":"R97-3-20211004","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, noninferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol"},{"key":"R98-3-20211004","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s40262-012-0010-0","article-title":"Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma","volume":"51","author":"Moreau","year":"2012","journal-title":"Clin Pharmacokinet"},{"key":"R99-3-20211004","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s40265-013-0006-6","article-title":"Subcutaneous bortezomib: in multiple myeloma","volume":"73","author":"Hoy","year":"2013","journal-title":"Drugs"},{"key":"R100-3-20211004","doi-asserted-by":"crossref","first-page":"e163","DOI":"10.1016\/j.clml.2015.07.377","article-title":"Subcutaneous administration of bortezomib significantly decreased and delayed the development of peripheral neuropathy in patients with newly diagnosed multiple myeloma","volume":"15","author":"Xu","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R101-3-20211004","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1177\/1060028013503122","article-title":"Subcutaneous versus intravenous bortezomib: efficiency practice variables and patient preferences","volume":"47","author":"Barbee","year":"2013","journal-title":"Ann Pharmacother"},{"key":"R102-3-20211004","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jama.2013.2813","article-title":"Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial","volume":"309","author":"Smith","year":"2013","journal-title":"JAMA"},{"key":"R103-3-20211004","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1124\/jpet.111.187401","article-title":"Etodolac, a cyclooxygenase-2 inhibitor, attenuates paclitaxel-induced peripheral neuropathy in a mouse model of mechanical allodynia","volume":"342","author":"Ito","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"R104-3-20211004","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jpainsymman.2007.02.043","article-title":"Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms","volume":"35","author":"Kautio","year":"2008","journal-title":"J Pain Symptom Manage"},{"key":"R105-3-20211004","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1007\/s00520-014-2158-7","article-title":"A phase III randomized, placebo-controlled study of topical amitriptyline and ketamine for chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study of 462 cancer survivors","volume":"22","author":"Gewandter","year":"2014","journal-title":"Support Care Cancer"},{"key":"R106-3-20211004","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s00520-010-0911-0","article-title":"A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA","volume":"19","author":"Barton","year":"2011","journal-title":"Support Care Cancer"},{"key":"R107-3-20211004","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1526-4637.2007.00301.x","article-title":"Experimental studies of potential analgesics for the treatment of chemotherapy-evoked painful peripheral neuropathies","volume":"9","author":"Xiao","year":"2008","journal-title":"Pain Med"},{"key":"R108-3-20211004","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1097\/FBP.0000000000000090","article-title":"Optimization and pharmacological characterization of a refined cisplatin-induced rat model of peripheral neuropathic pain","volume":"25","author":"Han","year":"2014","journal-title":"Behav Pharmacol"},{"key":"R109-3-20211004","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/00001813-200506000-00015","article-title":"Clinical activity of venlafaxine and topiramate against oxaliplatin-induced disabling permanent neuropathy","volume":"16","author":"Durand","year":"2005","journal-title":"Anticancer Drugs"},{"key":"R110-3-20211004","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2220\/biomedres.34.105","article-title":"Effects of repeated milnacipran and fluvoxamine treatment on mechanical allodynia in a mouse paclitaxel-induced neuropathic pain model","volume":"34","author":"Katsuyama","year":"2013","journal-title":"Biomed Res"},{"key":"R111-3-20211004","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.pbb.2010.02.009","article-title":"Antinociceptive effect of three common analgesic drugs on peripheral neuropathy induced by paclitaxel in rats","volume":"95","author":"Pascual","year":"2010","journal-title":"Pharmacol Biochem Behav"},{"key":"R112-3-20211004","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1248\/bpb.34.1377","article-title":"Antinociceptive efficacy of verticinone in murine models of inflammatory pain and paclitaxel induced neuropathic pain","volume":"34","author":"Xu","year":"2011","journal-title":"Biol Pharm Bull"},{"key":"R113-3-20211004","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.neulet.2009.09.003","article-title":"Increase in morphine antinociceptive activity by a P-glycoprotein inhibitor in cisplatin-induced neuropathy","volume":"465","author":"Balayssac","year":"2009","journal-title":"Neurosci Lett"},{"key":"R114-3-20211004","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1002\/cncr.23008","article-title":"Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3)","volume":"110","author":"Rao","year":"2007","journal-title":"Cancer"},{"key":"R115-3-20211004","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.neuroscience.2006.09.044","article-title":"Chemotherapy-evoked painful peripheral neuropathy: analgesic effects of gabapentin and effects on expression of the alpha-2-delta type-1 calcium channel subunit","volume":"144","author":"Xiao","year":"2007","journal-title":"Neuroscience"},{"key":"R116-3-20211004","doi-asserted-by":"crossref","first-page":"e76772","DOI":"10.1371\/journal.pone.0076772","article-title":"Assessment of paclitaxel induced sensory polyneuropathy with \u2018catwalk\u2019 automated gait analysis in mice","volume":"8","author":"Huehnchen","year":"2013","journal-title":"PLoS One"},{"key":"R117-3-20211004","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.ejpn.2008.06.011","article-title":"Efficacy of pregabalin in neuropathic pain in paediatric oncological patients","volume":"13","author":"Vondracek","year":"2009","journal-title":"Eur J Paediatr Neurol"},{"key":"R118-3-20211004","first-page":"2927","article-title":"Role of pregabalin in treatment of oxaliplatin-induced sensory neuropathy","volume":"30","author":"Saif","year":"2010","journal-title":"Anticancer Res"}],"container-title":["Current Opinion in Supportive &amp; Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/01263393-201606000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T18:15:30Z","timestamp":1633544130000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01263393-201606000-00003"}},"subtitle":["pain-like behaviours in rodent models and their response to commonly used analgesics"],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":116,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/spc.0000000000000204","relation":{},"ISSN":["1751-4258"],"issn-type":[{"value":"1751-4258","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]}}}